SMARCB1（INI-1）缺陷型鼻窦癌：一种不断演变的实体。

Chung Sei Y, Kenee Parker, Mitton Tanner, Halderman Ashleigh

Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center Ringgold Standard Institution, Dallas, Texas, United States.

J Neurol Surg Rep. 2023 Jan 16;84(1):e1-e5. doi: 10.1055/a-1996-1283. eCollection 2023 Jan.

SMARCB1(INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity. There is currently a general consensus supporting multimodal therapy, though the optimal sequence of surgery, chemotherapy, and radiation has yet to be defined.

SMARCB1（INI-1）缺陷型鼻窦癌是一种罕见的、低分化肿瘤，预后较差。虽然历史上大多数被诊断为鼻窦未分化癌，但我们现在认为它是一种独特的实体。目前普遍支持多模式治疗，尽管手术、化疗和放疗的最佳顺序尚未确定。